title: Scleroderma therapy: clinical overview of current trends and future perspective.
abstract: Systemic sclerosis is a chronic autoimmune condition with a complex pathogenesis and a high rate of mortality and morbidity. Internal organ involvement requires interdisciplinary approach in individual patient management. New discoveries in the pathogenesis of scleroderma herald a drastic change in the traditional outlook to therapy and have led to the development of the target-based approach in management. The challenge at present is to translate these advances in molecular mechanisms into well-designed clinical trials that will recognize potential disease-modifying therapies. This article is an evidence-based review of prevailing treatment options and future therapeutic targets in systemic sclerosis.
authors.affiliation: T.N.M.C & BYL Nair Hospital, OPD 16, OPD building, Mumbai Central, Mumbai 400 008, India. dr.afshatopal@gmail.com
authors.forename: Afsha A
authors.initials: AA
authors.lastname: Topal
authors.forename: Rachita S
authors.initials: RS
authors.lastname: Dhurat
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D005355:Fibrosis / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy / Q000379:methods*; D012219:Rheumatology / Q000379:methods / Q000639:trends; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000235:genetics; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D007155:Immunologic Factors; D014665:Vasodilator Agents